In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Elevation Oncology (ELEV – Research Report). The company’s shares opened today at $4.99.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Revolution Medicines. According to TipRanks, Frahm has an average return of 30.5% and a 50.96% success rate on recommended stocks.
Currently, the analyst consensus on Elevation Oncology is a Strong Buy with an average price target of $7.00, a 40.28% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Elevation Oncology’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.64 million. In comparison, last year the company had a GAAP net loss of $38.84 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Elevation Oncology (ELEV) Company Description:
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Read More on ELEV:
- Elevation Oncology reports Q4 EPS (19c), consensus (24c)
- GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls
- Elevation Oncology initiated with an Outperform at JMP Securities
- Elevation Oncology doses first patient in Japan in Phase 1 trial of EO-3021
- Elevation Oncology price target raised to $6 from $1.50 at H.C. Wainwright
